Needham, in a research note to investors on the biotech industry, mentioned Avidity (RNA) and Phathom Pharmaceuticals (PHAT) as the most likely takeout targets under coverage. The firm sees Regeneron (REGN), Bayer (BAYRY), and Novo Nordisk (NVO) as the most likely to buy earlier-stage companies, and Takeda (TAK), Biogen (BIIB), Bristol Myers (BMY), and Pfizer (PFE) as most likely to buy late-stage companies.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RNA:
- Avidity Biosciences Positioned for Leadership in Muscular Dystrophy with Strategic Regulatory Advancements
- Raymond James Predicts Up to ~760% Surge for These 2 ‘Strong Buy’ Stocks
- Avidity Biosciences price target raised to $70 from $60 at Evercore ISI
- Avidity Biosciences: Promising Advancements and Strategic Positioning Drive Buy Rating
- Avidity Biosciences resumed with a Buy at Goldman Sachs